🇺🇸 FDA
Patent

US 12173317

Use of histone modifiers to reprogram effector T cells

granted A61KA61K35/17A61K40/11

Quick answer

US patent 12173317 (Use of histone modifiers to reprogram effector T cells) held by The Board of Regents of the University of Texas System expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K35/17, A61K40/11, A61K40/4272, A61K45/06